南新制藥(688189.SH)擬以部分超募資金投建“帕拉米韋生產基地三期工程項目”變更為“NX-2016”等5個項目
格隆匯3月26日丨南新制藥(688189.SH)公佈,公司原“帕拉米韋生產基地三期工程項目”投資總額為人民幣4.31億元,其中擬使用超募資金3.26億元,擬由公司和全資子公司廣州南鑫藥業有限公司在廣州南鑫藥業有限公司廠區內實施,計劃工程建築物總佔地面積9,314.00m2,總建築面積33,285.00m2。該項目尚未提交股東大會審議通過。
公司於2021年3月26日召開第一屆董事會第二十一次會議、第一屆監事會第十六次會議審議通過了《關於使用部分超募資金投資建設“帕拉米韋生產基地三期工程項目”變更為“NX-2016”等5個項目的議案》,具體調整如下:
公司擬將部分超募資金3.26億元用於“NX-2016”等5個項目,其中:NX-2016項目計劃使用超募資金7561.33萬元;GK激活劑項目計劃使用超募資金6331.79萬元;JAK3抑制劑項目計劃使用超募資金8412.14萬元;P2X3拮抗劑項目計劃使用超募資金8342.44萬元;研發實驗室建設項目計劃使用超募資金1943.03元,剩餘部分由公司以自有資金或自籌資金投入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.